Rosacea: An Update in Diagnosis, Classification and Management

This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.

Moisturizers and Cleansers in the Management of Skin Conditions Caused by Personal Protective Equipment and Frequent Handwashing

Routine moisturization with non-irritating, pH-adjusted, ceramide-based products and gentle cleansing with a pH-adjusted cleanser can treat the unique dermatological challenges posed by COVID-19.

Update on Drugs & Devices: July – August 2021

The update covers: Secukinumab for SC use - Cosentyx® (Novartis), Brincidofovir tablets and oral suspension - Tembexa® (Chimerix), Plasminogen, humantvmh - Ryplazim® (Liminal BioSciences), Halobetasol propionate lotion 0.01% w/w - Bryhali™ (Bausch Health), and Nomacopan for SC use (Akari Therapeutics).

Bimekizumab for Moderate-to-Severe Plaque Psoriasis

Bimekizumab is a novel treatment for moderate-to-severe plaque psoriasis that has shown promising efficacy and safety in clinical trials. By simultaneously targeting two components of the IL-17 pathway, IL-17A and IL-17F, the biologic can downregulate proinflammatory signaling and rapidly improve patients’ skin.

Prurigo Nodularis: Review and Emerging Treatments

Novel therapeutics are currently being explored for the treatment of Prurigo Nodularis. Nemolizumab and dupilumab both demonstrate promise in inhibiting specific central nervous system pathways responsible for transmission of the pruritic sensation.

Update on Drugs & Devices: May-June 2021

The update covers: Axatilimab IV injection - SNDX-6352 (Syndax Pharmaceuticals), Binimetinib tablets + encorafenib capsules - Mektovi® + Braftovi® (Pfizer Canada), Encapsulated cell therapy for Fabry disease - SIG-007 (Sigilon Therapeutics) and Oritavancin IV injection - Kimyrsa™ (Melinta Therapeutics).

Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy

Certolizumab Pegol appears to offer a safe and effective psoriasis treatment for patients who are considering pregnancy, pregnant, or lactating based on its pharmacokinetics and available safety data.

Utility of the Human Papillomavirus Vaccination in Management of HPV-associated Cutaneous Lesions

HPV vaccines (Gardasil and Cervarix) may indeed have a therapeutic role in patients who suffer from dermatologic conditions that are associated with various strains of HPV.

Skin Treatments Introduced in 2020

This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.

Update on Drugs & Devices: March-April 2021

The update covers: Cemiplimab-rwlc for IV injection - Libtayo® (Regeneron/Sanofi), HA-based dermal filler - Restylane® Defyne™ (Galderma), Tirbanibulin ointment 1% - Klisyri® (Almirall/Athenex), Anakinra for SC use - Kineret® (Swedish Orphan Biovitrum Sobi™), Immune modulatory vaccines for melanoma - IO102 and IO103 (IO Biotech).

Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients With Oncology Treatment-Related Skin Toxicities

The CaSMO (Canadian Skin Management in Oncology) algorithm focuses on general skincare measures to prevent or reduce the severity of cancer-treatment-related cutaneous toxicities.

Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis

Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.

Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis

Early clinical trial data indicate the increasing effectiveness and safety of efinaconazole 10% solution use beyond 12 months; application for up to 24 months appears to remain safe even for elderly patients.

2020 Index for Skin Therapy Letter – Dermatology Edition

This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.

Update on Drugs & Devices: January-February 2021

The latest drug & device update covers: Orladeyo™ (BioCryst Pharmaceuticals), KPL-716 (Kiniksa Pharmaceuticals), Sklice® (Arbor Pharmaceuticals) and Picato® (Leo Pharma)

Pediatric Psoriasis Comorbidities

While the association between psoriasis and various comorbidities is well documented in adults, questions remain as to whether the same relationships exist in the pediatric population.

Nicotinamide: An Update and Review of Safety & Differences from Niacin

Oral nicotinamide is an affordable over-the-counter supplement with demonstrated benefit in the treatment of a range of skin conditions, most notably AK and NMSC.

Update on Drugs & Devices: November – December 2020

This update covers: Gene therapy for DEB (AGLE-102), Golimumab for IV use (Simponi® Aria™), Clascoterone 1% cream (Winlevi®), Triplet melanoma therapy (Tecentriq® + Cotellic® and Zelboraf®), Ustekinumab for SC use (Stelara®), Calcipotriene + betamethasone dipropionate cream (Wynzora®), Abametapir 0.74% lotion (Xeglyze™), Sonidegib capsules (Odomzo®) and Halobetasol propionate + tazarotene lotion (Duobrii™).

Colloidal Oatmeal use in Dermatology (Supplement)

There is mounting evidence that colloidal oatmeal can safely enhance skin hydration and even help resolve clinical lesions through anti-inflammatory effects and by modulation of the microbiome.

Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors

Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, represent a new class of medication that have broad potential to treat dermatologic disease.

Elective Treatment of Dermatosis Papulosa Nigra: A Review of Treatment Modalities

Dermatosis papulosa nigra is a benign skin lesion found most frequently on the face of patients with skin of color. This article compares treatment modalities for DPN.

Update on Drugs & Devices: September-October 2020

This update covers: Guselkumab SC use (Tremfya®), Adalimumab-fkjp SC use (Hulio®), Collagenase clostridium histolyticum-aaes SC use (Qwo™), Protein replacement therapy for XLHED (ER-004), Pembrolizumab IV use (Keytruda®), Minocycline 1.5% foam (Zilxi™), Microbiome-based non-aqueous ointment (ATR-12), Dupilumab SC use (Dupixent®) and Selumetinib capsules (Koselugo™)

The Role of Skin Care in Oncology Patients

The consensus paper aims to identify the impact on patients of skin toxicities associated with cancer treatment and evidence-based best practices for skincare to minimize or prevent these changes.

Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature

The addition of biologics that target IL-23p19 (Risankizumab) to our therapeutic armamentarium has succeeded in improving outcomes in patients with moderate-to-severe plaque psoriasis.

Management of Primary Small-Vessel Vasculitis

Small-vessel vasculitides (SVV) are a group of disorders that occur due to primarily systemic inflammation or as sequelae of an infection, malignancy, or other rheumatic disease.

Update on Drugs & Devices: May – June 2020

Update on Selumetinib capsules (Koselugo®), Crisaborole 2% ointment (Eucrisa®), Infliximab biosimilar for IV injection (Avsola™) and Baricitinib tablets (Olumiant®)

Use of Topical Crisaborole for Treating Dermatitis in a Variety of Dermatology Settings

The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.

A Novel Topical Retinoid for Acne: Trifarotene 50 μg/g Cream

In two large randomized vehicle-controlled 12-week trials and in a 52-week open label study of moderate-to-severe acne at the face and trunk in subjects aged 9 years and older, trifarotene 50 μg/g cream demonstrated efficacy, safety, and cutaneous tolerability.

An Anti-Wrinkle Diet: Nutritional Strategies to Combat Oxidation, Inflammation and Glycation

A number of research studies have documented the link between diet and skin aging. These results may be used to develop dietary recommendations that combat the forces of oxidation, inflammation, and glycation.

Skin Treatments Introduced in 2019

A variety of new skin treatments introduced in 2019.

Update on Drugs & Devices: March – April 2020

This update covers Tazemetostat tablets/Tazverik™ (Epizyme, Inc.), Tazarotene lotion 0.045%/Arazlo™ (Ortho Dermatologics, Bausch Health) and Rituximab biosimilar for IV injection/ABP 798 (Amgen, Allergan).

Hydrogen Peroxide Topical Solution, 40% (w/w) for the Treatment of Seborrheic Keratoses: A Review

Given our current options for the treatment of Seborrheic Keratoses include only more invasive, non-topical therapies, Hydrogen Peroxide Topical Solution (40%) fills a void in our therapeutic repertoire as the first FDA-approved topical therapy for SKs.

Management of Ichthyosis: A Brief Review

Ichthyosis management requires a multimodal approach, including topical and oral agents in addition to lifestyle modifications.

Update on Drugs & Devices: January – February 2020

This update covers Lebrikizumab SC injection (Dermira), Infliximab-axxq for IV injection (Avsola™, Amgen), Trifarotene cream 50 mcg/g (Aklief®, Galderma), Adalimumab-afzb for SC injection (Abrilada™, Pfizer), Lidocaine + tetracaine (7%/7%) local anesthetic cream (Pliaglis®, Crescita Therapeutics), Maralixibat oral solution (Mirum Pharmaceuticals), Cetirizine hydrochloride for IV injection (Quzyttir™, TerSera Therapeutics) and Minocycline foam 4% (Amzeeq™, Foamix)

Index for STL Volume 24 (2019)

Index of STL articles for Volume 24 (2019). Articles are indexed by drug names, trade names and disease terms. Use the main navigation (A, B, C..) to navigate through this index and use the reference links (i.e. 4:5-9) to see the sources.

Tildrakizumab for Moderate-to-Severe Plaque Psoriasis

Tildrakizumab is a promising therapeutic option for patients with moderate-to-severe chronic plaque psoriasis. The specificity of the drug in targeting the p19 subunit of IL-23 allows for the high efficacy and safety of long-term treatment as demonstrated in clinical trials.

Brief Update on Dermatologic Uses of Methotrexate

Methotrexate has been an important agent in the management of dermatologic conditions for decades. Although first indicated for the treatment of psoriasis, MTX has been shown to be a successful treatment option for a wide array of skin diseases.

Update on Drugs & Devices: November – December 2019

The latest drug & device update covers: Trifarotene 0.005% cream (Aklief®, Galderma), Afamelanotide implant (Scenesse®, Clinuvel Pharmaceuticals), Rituximab for IV use (Rituxan®, Genentech), Jynneos™ (Bavarian Nordic), Aczone® (Almirall) and Juvéderm Voluma® XC (Allergan)

Platelet-Rich Plasma (PRP): Current Applications in Dermatology

Platelet-rich plasma (PRP) is an autologous serum containing high concentrations of platelets and growth factors. PRP continues to evolve as an important treatment modality with many applications in dermatology, particularly in the areas of hair restoration, skin rejuvenation, acne scars, dermal augmentation, and striae distensae.

Skin, Hair and Nail Supplements: An Evidence-Based Approach

Dermatology supplements, often marketed as “skin, hair, and nail” supplements, are becoming increasingly popular. However, many consumers lack an understanding of the science of dietary supplements or the specifics of the supplement industry.

POPULAR